Nanobiotix SA

Nanobiotix SA engages in research and development of nanoparticle-based technologies for the treatment of cancer. The company's technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. It also engages in the development of magnetic particles and laser activated nanoparticles for the treatment and diagnosis of cancer. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.

PARIS and CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the availability of the listing prospectus approved by the French Financial Markets Authority (Autorité des Marchés Financiers – the “ AMF ”) under number 23-461, on November 3, 2023, in the context of two share capital increases of an aggregate gross amount of approximately $50 million. million as well as the partial exercise of the over-allotment option granted to the underwriters by the Company for an additional amount of approximately $3.6M.

NANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M

PARIS and CAMBRIDGE, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the pricing of its previously announced global follow-on offering reserved to specified categories of investors, consisting of (i) an offering of 3,106,907 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) at an offering price of $5.36 per ADS, and (ii) an offering of 2,492,223 Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) and certain other countries (excluding the United States and Canada) (the “European Offering”) at an offering price of €5.07 per Ordinary Share. The U.S. Offering and the European Offering are referred to, together, as the “Global Offering.”

NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M

PARIS and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – “Nanobiotix” or the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announces the launch, subject to market and other conditions, of an approximately $30.0 million global follow-on offering (representing approximately €28.4 million) reserved to specified categories of investors consisting of (i) an offering of its American Depositary Shares (“ADSs”), each representing one ordinary share, €0.03 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “U.S. Offering”) and (ii) an offering of its Ordinary Shares, exclusively to “qualified investors” in Europe (including France) within the meaning of Article 2(e) of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”), and certain other countries (excluding the United States and Canada) (the “European Offering”). The U.S. Offering and the European Offering are referred to, together, as the “Global Offering”.

NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer (LAPC) established a favorable safety profile and recommended dose 23 months median Overall Survival (mOS) observed in 17 patients treated with cytotoxic chemotherapy followed by RT-activated NBTXR3 Review of an historical control from the same center as this Phase 1 in 243 patients with LAPC showed an mOS of 19.2 months in 144 patients who received cytotoxic chemotherapy followed by RT with or without concurrent or maintenance chemotherapy (80% received RT with concurrent chemotherapy) The investigator concluded that these results suggest promising anti-tumor efficacy for NBTXR3 in LAPC Nanobiotix-presented Study 102 Exploratory Analysis New exploratory analysis of completed Study 102 sought additional signs of efficacy in the evaluable population (n=44) as strong support for the hypotheses underlying the design of the Company's ongoing registrational Phase 3 study (NANORAY-312) 42.8 months mOS observed in the 81.8% of evaluable patients who had complete or partial response in the NBTXR3-injected lesion (36/44) compared to 18.1 months in All Patients Treated (n=56) Analysis showed a positive correlation between Objective Response to RT-activated NBTXR3 in the injected lesion, along with injected-lesion Progression-Free Survival, and the extension of OS for elderly, frail patients with head and neck cancer These data suggest that the high rate of Objective Response to RT-activated NBTXR3 could potentially extend PFS and OS for elderly, frail patients with locally advanced head and neck cancer PARIS and CAMBRIDGE, Mass., Oct. 23, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced updated data from two presentations at the 2023 Annual Congress of the European Society for Medical Oncology (ESMO).

NANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society for Radiation Oncology Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society for Radiation Oncology

Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Month

Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CEST

NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research

NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

Nanobiotix S.A. (NASDAQ:NBTX ) Q2 2023 Earnings Conference Call September 27, 2023 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder & CEO Bart Van Rhijn - CFO Conference Call Participants Lucy Codrington - Jefferies Swayampakula Ramakanth - H.C.

Nanobiotix S.A. (NBTX) Q2 2023 Earnings Call Transcript

Global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”) expands worldwide potential of novel radioenhancer NBTXR3 Upfront payment and first equity tranche received by Nanobiotix post H1 2023 from agreement with Janssen extends cash runway into the first quarter of 2024 and second quarter if the cash covenant of the European Investment Bank (EIB) was not applicable Bolstering of clinical oncology development and commercialization capabilities with appointment of Louis Kayitalire, MD as chief medical officer (CMO) Final Phase 1 safety and efficacy data in head and neck cancer, and initial Phase 1 dose escalation data in pancreatic cancer for NBTXR3 expected in the coming weeks Reported €21.6 million in cash and cash equivalents as of June 30, 2023 Reached agreement in principle with the EIB to remove the cash covenant in its entirety, subject to certain conditions Conference call and webcast scheduled for Wednesday, September 27, 2023, at 2:00 pm CEST / 8:00 am EDT PARIS and CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2023.

NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023 Conference Call and Webcast to be Held at 8:00 AM EDT / 2:00 PM CEST on September 27, 2023

Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023

PARIS and CAMBRIDGE, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the appointment of Louis Kayitalire, MD, as chief medical officer. Dr. Kayitalire brings an exceptional biopharmaceutical industry track record with proven success in the research, development, registration, and commercialization of therapeutics in oncology.

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

PARIS and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Laurent Levy, co-founder of Nanobiotix and chairman of the executive board, and Bart Van Rhijn, chief financial officer, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 4:00 PM EDT / 10:00 AM CEST.

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Nanobiotix is an oncology-focused biotech aiming for its first drug approval, with a tripled value since the beginning of 2023. Their flagship molecule, NBTX3-RT, is showing promising results in enhancing the efficacy of radiotherapy for various solid tumors. A recent licensing agreement with Janssen provides significant funding and de-risking for Nanobiotix's next steps.

Nanobiotix: At A Crucial Juncture For Data

PARIS and CAMBRIDGE, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 for its previously announced (July 10, 2023) global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

PARIS and CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company will host an Extraordinary General Meeting of Shareholders (“EGM”) on September 1st, 2023 at 02:00 pm CEST at its headquarters.

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

PARIS and CAMBRIDGE, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO — NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the first patient has been injected in a Phase 1/2 study evaluating NBTXR3 activated by radiation therapy in combination with anti-PD-1/L-1 immune checkpoint inhibitors for the treatment of patients with advanced solid tumor malignancies that have spread to lungs (lung metastases) and/or liver (liver metastases). The trial (NCT05039632) is being conducted as part of an ongoing strategic collaboration between Nanobiotix and The University of Texas MD Anderson Cancer Center evaluating radiotherapy-activated NBTXR3 across solid tumor indications and treatment combinations.

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Johnson & Johnson

French biotechnology company Nanobiotix has entered into an agreement with J&J's wholly-owned medical research and pharmaceutical arm Janssen to license, co-develop and commercialize a drug to treat head and neck cancer tumours, sending the company's shares soaring.  The agreement relates to Nanobiotix's radioenhancer NBTXR3 which is being evaluated in a Phase 3 study for the treatment of patients with locally advanced head and neck cancer and for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.

Nanobiotix surges on commercialization deal with J&J's Janssen for cancer therapeutic

American depositary receipts of Nanobiotix jumped over 50% in early trading on Monday after signing an agreement with J&J's Janssen Pharmaceutical to work on co-developing a drug to treat head and neck cancer tumors.

Nanobiotix ADRs Jump Over 50% After Agreement With J&J's Janssen Pharmaceutical

Shares of Nanobiotix SA NBTX, +1.57% shot up 52.1% toward a 17-month high in premarket trading Monday, after the France-based biotechnology company announced a global licensing and co-development agreement with Johnson & Johnson's JNJ, -1.45% Janssen Pharmaceutica NV for its cancer treatment. Under terms of the agreement, Nanobiotix will receive up to $60 million in cash near-term, including $30 million for licensing and up to $30 to help develop for NBTXR3, which is being evaluated for treatment of head and neck cancer.

Nanobiotix's stock soars after entering licensing, development deal with J&J's Janssen Pharmaceutica

PARIS and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for the investigational, potential first-in-class radioenhancer NBTXR3.

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

Reported €30.2 million in cash and cash equivalents as of March 31, 2023 Reported €30.2 million in cash and cash equivalents as of March 31, 2023

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

Nanobiotix SA (EPA:NANO) shares soared 250% to $7.11, on volume of more than 29 million shares, Friday after the France-based clinical biotechnology company said it has entered into final contract negotiations with a “major global pharmaceutical company” for the commercialization of Nanobiotix's cancer treatment. Nanobiotix said negotiations come after an agreement to a non-binding term sheet for development and commercialization of its lead nanotherapeutic candidate NBTXR3.

Nanobiotix stock skyrockets on final negotiations with ‘major' drug maker for its cancer treatment

The U.S.-listed shares of Nanobiotix S.A. NBTX blasted 221.7% higher on massive volume Friday, to pace all gainers trading on major U.S. exchanges, after the France-based biotechnology company said it entered into final contract negotiations for the commercialization of its cancer treatment.

Nanobiotix stock more than triples, after biotech enters final negotiations with ‘major' drug maker on development of cancer treatment

Nanobiotix (NASDAQ: NBTX ) stock is taking off on Friday after the company revealed details about ongoing contract negotiations for NBTXR3. NBTXR3 is Nanobiotix's treatment in the works for solid tumors.

Why is Nanobiotix (NBTX) Stock Up 107% Today?

PARIS and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), today announced that the Company is entering into final contract negotiations after agreement to a non-binding term sheet for development and commercialization of lead nanotherapeutic candidate NBTXR3 with a major global pharmaceutical company, following an extensive negotiation period.

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

News for Nanobiotix SA Stock (NBTX)